UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 341

Sortiert nach

Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

International journal of molecular sciences, 2021-01, Vol.22 (2), p.883

2021

Volltextzugriff (PDF)

ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3725

2023

Volltextzugriff (PDF)

Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis

Journal of thrombosis and haemostasis, 2019-06, Vol.17 (6), p.878-884

2019

Volltextzugriff (PDF)

Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis

Pharmaceutics, 2021-10, Vol.13 (10), p.1731

2021

Volltextzugriff (PDF)

Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

Thrombosis and haemostasis, 2005-09, Vol.94 (3), p.471

2005

Volltextzugriff (PDF)

Measurement of Procarboxypeptidase U (TAFI) in Human Plasma: A Laboratory Challenge

Clinical chemistry (Baltimore, Md.), 2006-01, Vol.52 (1), p.30-36

2006

Volltextzugriff (PDF)

Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis

Journal of clinical medicine, 2022-03, Vol.11 (6), p.1494

2022

Volltextzugriff (PDF)

Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay

Analytical biochemistry, 2010-08, Vol.403 (1-2), p.114-116

2010

Volltextzugriff (PDF)

A role for procarboxypepidase U (TAFI) in thrombosis

Frontiers in bioscience, 2007-01, Vol.12, p.1973

2007

Volltextzugriff (PDF)

Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma

Analytical biochemistry, 2010, Vol.396 (1), p.152-154

2010

Volltextzugriff (PDF)

The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays

Analytical biochemistry, 2006-09, Vol.356 (1), p.157-159

2006

Volltextzugriff (PDF)

Plasma procarboxypeptidase U in men with symptomatic coronary artery disease

Thrombosis and haemostasis, 2000-09, Vol.84 (3), p.364

2000

Volltextzugriff (PDF)

Major carboxypeptidase N deficiency

Clinica chimica acta, 2008-03, Vol.389 (1-2), p.181-182

2008

Volltextzugriff (PDF)

Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: Development of highly selective CPU substrates as useful tools for assay development

Clinica chimica acta, 2008-01, Vol.387 (1-2), p.158-160

2008

Volltextzugriff (PDF)

Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate

Analytical biochemistry, 2005-05, Vol.340 (1), p.106-112

2005

Volltextzugriff (PDF)

The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over

Biochimica et biophysica acta, 2007-02, Vol.1774 (2), p.267-277

2007

Volltextzugriff (PDF)

Development of a genotype 325-specific proCPU/TAFI ELISA

Arteriosclerosis, thrombosis, and vascular biology, 2003-06, Vol.23 (6), p.1122

2003

Volltextzugriff (PDF)

Assay of Procarboxypeptidase U, a Novel Determinant of the Fibrinolytic Cascade, in Human Plasma

Clinical chemistry (Baltimore, Md.), 1999-06, Vol.45 (6), p.807-813

1999

Volltextzugriff (PDF)

Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients

Clinical neurology and neurosurgery, 2009-02, Vol.111 (2), p.165-170

2009

Volltextzugriff (PDF)

A rapid and sensitive assay for the quantitation of carboxypeptidase N, an important regulator of inflammation

Clinica chimica acta, 2006-09, Vol.371 (1), p.124-129

2006

Volltextzugriff (PDF)

Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma

Thrombosis and haemostasis, 2003-02, Vol.89 (2), p.264

2003

Volltextzugriff (PDF)

Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study

Clinical therapeutics, 2021-05, Vol.43 (5), p.908-916

2021

Volltextzugriff (PDF)

Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals

Journal of thrombosis and haemostasis, 2023-05, Vol.21 (5), p.1266-1273

2023

Volltextzugriff (PDF)

Proteolytic activation of purified human procarboxypeptidase U

Clinica chimica acta, 2000-02, Vol.292 (1), p.25-40

2000

Volltextzugriff (PDF)

Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis

Thrombosis and haemostasis, 2017, Vol.117 (8), p.1498

2017

Volltextzugriff (PDF)

1 – 25 von 341

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(234)
Mit Volltextzugriff
(299)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(308)
Deutsch
(36)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation

Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis

Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis

Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

Measurement of Procarboxypeptidase U (TAFI) in Human Plasma: A Laboratory Challenge

Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis

Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay

A role for procarboxypepidase U (TAFI) in thrombosis

Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma

The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays

Plasma procarboxypeptidase U in men with symptomatic coronary artery disease

Major carboxypeptidase N deficiency

Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: Development of highly selective CPU substrates as useful tools for assay development

Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate

The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over

Development of a genotype 325-specific proCPU/TAFI ELISA

Assay of Procarboxypeptidase U, a Novel Determinant of the Fibrinolytic Cascade, in Human Plasma

Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients

A rapid and sensitive assay for the quantitation of carboxypeptidase N, an important regulator of inflammation

Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma

Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study

Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals

Proteolytic activation of purified human procarboxypeptidase U

Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis

Suchergebnisse filtern